Cargando…

Report and follow-up on two new patients with congenital mesoblastic nephroma

BACKGROUND: Tumors are rare in neonatal age. Congenital mesoblastic nephroma (CMN) is a usually benign renal tumor observed at birth, or in the first months of life. It may also be identified prenatally and associated with polyhydramnios leading to preterm delivery. Effective treatment is surgical i...

Descripción completa

Detalles Bibliográficos
Autores principales: Serra, Gregorio, Cimador, Marcello, Giuffrè, Mario, Insinga, Vincenzo, Montante, Claudio, Pensabene, Marco, Piro, Ettore, Salerno, Sergio, Schierz, Ingrid Anne Mandy, Corsello, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510132/
https://www.ncbi.nlm.nih.gov/pubmed/37726782
http://dx.doi.org/10.1186/s13052-023-01523-7
_version_ 1785107899682390016
author Serra, Gregorio
Cimador, Marcello
Giuffrè, Mario
Insinga, Vincenzo
Montante, Claudio
Pensabene, Marco
Piro, Ettore
Salerno, Sergio
Schierz, Ingrid Anne Mandy
Corsello, Giovanni
author_facet Serra, Gregorio
Cimador, Marcello
Giuffrè, Mario
Insinga, Vincenzo
Montante, Claudio
Pensabene, Marco
Piro, Ettore
Salerno, Sergio
Schierz, Ingrid Anne Mandy
Corsello, Giovanni
author_sort Serra, Gregorio
collection PubMed
description BACKGROUND: Tumors are rare in neonatal age. Congenital mesoblastic nephroma (CMN) is a usually benign renal tumor observed at birth, or in the first months of life. It may also be identified prenatally and associated with polyhydramnios leading to preterm delivery. Effective treatment is surgical in most cases, consisting in total nephrectomy. In literature, very few studies report on the neonatal management of such a rare disease, and even less are those describing its uncommon complications. CASES PRESENTATION: We report on two single-center newborns affected with CMN. The first patient is a preterm female baby, born at 30(+ 1) weeks of gestation (WG) due to premature labor, with prenatal (25 WG) identification of an intra-abdominal fetal mass associated with polyhydramnios. Once obtained the clinical stability, weight gain, instrumental (computed tomography, CT, showing a 4.8 × 3.3 cm left renal neoformation) and histological/molecular characterization of the lesion (renal needle biopsy picture of classic CMN with ETV6-NTRK3 translocation), a left nephrectomy was performed at 5 weeks of chronological age. The following clinical course was complicated by intestinal obstruction due to bowel adherences formation, then by an enterocutaneous fistula, requiring multiple surgical approaches including transitory ileo- and colostomy, before the conclusive anastomoses intervention. The second patient is a 17-day-old male term baby, coming to our observation due to postnatal evidence of palpable left abdominal mass (soon defined through CT, showing a 7.5 × 6.5 cm neoformation in the left renal lodge), feeding difficulties and poor weight gain. An intravenous diuretic treatment was needed due to the developed hypertension and hypercalcemia, which regressed after the nephrectomy (histological diagnosis of cellular CMN with ETV6-NTRK3 fusion) performed at day 26. In neither case was chemotherapy added. Both patients have been included in multidisciplinary follow-up, they presently show regular growth and neuromotor development, normal renal function and no local/systemic recurrences or other gastrointestinal/urinary disorders. CONCLUSIONS: The finding of a fetal abdominal mass should prompt suspicion of CMN, especially if it is associated with polyhydramnios; it should also alert obstetricians and neonatologists to the risk of preterm delivery. Although being a usually benign condition, CMN may be associated with neonatal systemic-metabolic or postoperative complications. High-level surgical expertise, careful neonatological intensive care and histopathological/cytogenetic-molecular definition are the cornerstones for the optimal management of patients. This should also include an individualized follow-up, oriented to the early detection of any possible recurrences or associated anomalies and to a better quality of life of children and their families.
format Online
Article
Text
id pubmed-10510132
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105101322023-09-21 Report and follow-up on two new patients with congenital mesoblastic nephroma Serra, Gregorio Cimador, Marcello Giuffrè, Mario Insinga, Vincenzo Montante, Claudio Pensabene, Marco Piro, Ettore Salerno, Sergio Schierz, Ingrid Anne Mandy Corsello, Giovanni Ital J Pediatr Case Report BACKGROUND: Tumors are rare in neonatal age. Congenital mesoblastic nephroma (CMN) is a usually benign renal tumor observed at birth, or in the first months of life. It may also be identified prenatally and associated with polyhydramnios leading to preterm delivery. Effective treatment is surgical in most cases, consisting in total nephrectomy. In literature, very few studies report on the neonatal management of such a rare disease, and even less are those describing its uncommon complications. CASES PRESENTATION: We report on two single-center newborns affected with CMN. The first patient is a preterm female baby, born at 30(+ 1) weeks of gestation (WG) due to premature labor, with prenatal (25 WG) identification of an intra-abdominal fetal mass associated with polyhydramnios. Once obtained the clinical stability, weight gain, instrumental (computed tomography, CT, showing a 4.8 × 3.3 cm left renal neoformation) and histological/molecular characterization of the lesion (renal needle biopsy picture of classic CMN with ETV6-NTRK3 translocation), a left nephrectomy was performed at 5 weeks of chronological age. The following clinical course was complicated by intestinal obstruction due to bowel adherences formation, then by an enterocutaneous fistula, requiring multiple surgical approaches including transitory ileo- and colostomy, before the conclusive anastomoses intervention. The second patient is a 17-day-old male term baby, coming to our observation due to postnatal evidence of palpable left abdominal mass (soon defined through CT, showing a 7.5 × 6.5 cm neoformation in the left renal lodge), feeding difficulties and poor weight gain. An intravenous diuretic treatment was needed due to the developed hypertension and hypercalcemia, which regressed after the nephrectomy (histological diagnosis of cellular CMN with ETV6-NTRK3 fusion) performed at day 26. In neither case was chemotherapy added. Both patients have been included in multidisciplinary follow-up, they presently show regular growth and neuromotor development, normal renal function and no local/systemic recurrences or other gastrointestinal/urinary disorders. CONCLUSIONS: The finding of a fetal abdominal mass should prompt suspicion of CMN, especially if it is associated with polyhydramnios; it should also alert obstetricians and neonatologists to the risk of preterm delivery. Although being a usually benign condition, CMN may be associated with neonatal systemic-metabolic or postoperative complications. High-level surgical expertise, careful neonatological intensive care and histopathological/cytogenetic-molecular definition are the cornerstones for the optimal management of patients. This should also include an individualized follow-up, oriented to the early detection of any possible recurrences or associated anomalies and to a better quality of life of children and their families. BioMed Central 2023-09-19 /pmc/articles/PMC10510132/ /pubmed/37726782 http://dx.doi.org/10.1186/s13052-023-01523-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Serra, Gregorio
Cimador, Marcello
Giuffrè, Mario
Insinga, Vincenzo
Montante, Claudio
Pensabene, Marco
Piro, Ettore
Salerno, Sergio
Schierz, Ingrid Anne Mandy
Corsello, Giovanni
Report and follow-up on two new patients with congenital mesoblastic nephroma
title Report and follow-up on two new patients with congenital mesoblastic nephroma
title_full Report and follow-up on two new patients with congenital mesoblastic nephroma
title_fullStr Report and follow-up on two new patients with congenital mesoblastic nephroma
title_full_unstemmed Report and follow-up on two new patients with congenital mesoblastic nephroma
title_short Report and follow-up on two new patients with congenital mesoblastic nephroma
title_sort report and follow-up on two new patients with congenital mesoblastic nephroma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510132/
https://www.ncbi.nlm.nih.gov/pubmed/37726782
http://dx.doi.org/10.1186/s13052-023-01523-7
work_keys_str_mv AT serragregorio reportandfollowupontwonewpatientswithcongenitalmesoblasticnephroma
AT cimadormarcello reportandfollowupontwonewpatientswithcongenitalmesoblasticnephroma
AT giuffremario reportandfollowupontwonewpatientswithcongenitalmesoblasticnephroma
AT insingavincenzo reportandfollowupontwonewpatientswithcongenitalmesoblasticnephroma
AT montanteclaudio reportandfollowupontwonewpatientswithcongenitalmesoblasticnephroma
AT pensabenemarco reportandfollowupontwonewpatientswithcongenitalmesoblasticnephroma
AT piroettore reportandfollowupontwonewpatientswithcongenitalmesoblasticnephroma
AT salernosergio reportandfollowupontwonewpatientswithcongenitalmesoblasticnephroma
AT schierzingridannemandy reportandfollowupontwonewpatientswithcongenitalmesoblasticnephroma
AT corsellogiovanni reportandfollowupontwonewpatientswithcongenitalmesoblasticnephroma